The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: A pilot study

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 8, Issue 2, 2003, Pages 127-134

  Rizos, Evangelos ^a   Bairaktari, Eleni ^b   Kostoula, Angeliki ^b   Hasiotis, George ^b   Achimastos, Apostolos ^c   Ganotakis, Emanuel ^d   Elisaf, Moses ^a,f   Mikhailidis, D P ^e  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Atenolol; Combination treatment; HOMA index; Nebivolol; Pravastatin; Triglycerides

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; ATENOLOL; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEBIVOLOL; PRAVASTATIN; TRIACYLGLYCEROL; URIC ACID;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE REGULATION; CARBOHYDRATE INTOLERANCE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; ENZYME RELEASE; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC REGULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL;

EID: 0038170610     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840300800206     Document Type: Article

References (55)

1. Pessina AC. Metabolic effects and safety profile of nebivolol. J Cardiovasc Pharmacol 38:S33-S55, 2001
2. McNeely W, Goa KL. Nebivolol in the management of essential hypertension: A review. Drugs 57:633-651, 1999
3. Troost R, Schwedhelm E, Rojczyk S, et al. Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol 50:37-39, 2000
4. Auer J, Berent R, Weber T, et al. Clinical significance of pleiotropic effects of statins: Lipid reduction and beyond. Curr Med Chem 9:1831-1850, 2002
5. Reneland R, Alvarez E, Andersson PE, et al. Induction of, insulin resistance by beta-blockade but not ACE-inhibition: Long-term with atenolol or trandolapril. J Hum Hypertens 14:175-180, 2000
6. Fogari R, Zoppi A, Corradi L, et al. Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 33:534-539, 1999
7. Gordon NF, Scott CB, Duncan JJ. Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men. Am J Cardiol 79:1065-1069, 1997
8. Aberg H, Morlin C, Lithell H. Different long-term metabolic effects of enalapril and atenolol in patients with mild hypertension. EGTA Group. J Hum Hypertens 9:149-153, 1995
9. Pesant Y, Marc-Aurele J, Bielmann P, et al. Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension. Am J Ther 6:137-147, 1999
10. Rabkin SW, Huff MW, Newman C, et al. Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: The Alpha Beta Canada Study. Hypertension 24:241-248, 1994
11. Lind L, Pollare T, Berne C, et al. Long-term metabolic effects of antihypertensive drugs. Am Heart J 128:1177-1183, 1994
12. Von Fallois J, Faulhaber HD. Nebivolol, a beta blocker of the 3rd generation: Modern therapy of arterial hypertension. Results of a multicenter observation study. Scheiz Rundsch Med Prax 90:435-441, 2001
13. Lacourciere Y, Poirier L, Lefebvre J, et al. Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol 32:660-666, 1992
14. Lacourciere Y, Arnott W. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hyperns 8:283-288, 1994
15. Reusch JE. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol 90:19G-26G, 2002
16. Makris TK, Stavroulakis GA, Krespi PG, et al. Fibrinolytic/hemostatic variables in arterial hypertension: Response to treatment with irbesartan or atenolol. Am J Hypertens 13:783-788, 2000
17. Fogari R, Zoppi A, Malamani GD, et al. Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients. Br J Clin Pharmacol 39:471-476, 1995
18. Papadakis JA, Ganotakis ES, Jagroop IA, Mikhailidis DP, Winder AF. Effect of hypertension and its treatment on lipid, lipoprotein (a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens 12:673-681, 1999
19. Jenkins NP, Keevil BG, Hutchinson IV, et al. Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease. Am J Med 112:269-274, 2002
20. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 288:2015-2022, 2002
21. Virdis A, Ghiadoni L, Salvetti G, et al. Hyperhomocysteinemia: Is this a novel risk factor in hypertension? J Nephrol 15:414-421, 2002
22. Wocial B, Berent H, Kostruciec M, et al. Homocysteine, adrenergic activity and left ventricular mass in patients with essential hypertension. Blood Press 11:201-205, 2002
23. Chrysant SG, Chappel C, Farnham DJ, et al. Antihypertensive and metabolic effects of single and combined atenolol regimens. J Clin Pharmacol 32:61-65, 1992
24. Lehtonen A. Comparison of the metabolic effects of long-term treatment with pindolol or atenolol by hypertensive patients. Cardiovasc Drugs Ther 1:549-551, 1988
25. Helgeland A, Strommen R, Hagelund CH. Enalapril, atenolol, and hydrochlorothiazide in, mild to moderate hypertension. A comparative multicentre study in general practice in Norway. Lancet 1:872-875, 1986
26. Andersen GS. Atenolol versus bendroflumethiazide in middle-aged and elderly hypertensives. Acta Med Scand 218:165-172, 1985
27. Salvadeo A, Villa G, Segagni S, et al. Pressure and humoral changes induced by atenolol and hydrochlorothiazide + amiloride, alone and in free combination. A comparative between-patient study. Int J Clin Pharmacol Res 3:371-377, 1983
28. Gostick NK, Mayhew SR, Million R, et al. A dose-response study of atenolol in mild to moderate hypertension in general practice. Curr Med Res Opin 5:179-184, 1977
29. Krusell LR, Jespersen LT, Christensen CK. Proximal tubular function in essential hypertensives on beta-blocker therapy with atenolol. Blood Press 6:166-170, 1997
30. Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly program (SHEP). J Hypertens 18:1149-1154, 2000
31. Poirier L, Cleroux J, Nadeau A, et al. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 19:1429-1435, 2001
32. Kuperstein R, Sasson Z. Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: A randomized, double-blind, controlled study of 21 obese hypertensives. Circulation 102:1802-1806, 2000
33. Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: To what extend is the reduction in coronary events with pravastatin explained by on-study lipid levels. Circulation 105:1162-1169, 2002
34. Ballantyne CM, Andrews TC, Hsia JA, et al. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: Effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 88:265-269, 2001
35. Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102:1886-1892, 2000
36. Dallongeville J, Fruchart JC, Maigret P, et al. Double-blind comparison of apolipoprotein and lipoprotein particle lowering effects of atorvastatin and pravastatin monotherapy in patients with primary hypercholesterolemia. J Cardiovasc Pharmavol Ther 3:103-110, 1998
37. Lijnen P, Celis H, Desager JP, et al. Changes in plasma lipids, lipoproteins and apolipoproteins in hypercholesterolaemic patients treated with pravastatin. J Hum Hypertens 9:557-564, 1995
38. Hunninghake DB, Stein EA, Mellies MJ. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein (a). J Clin Pharmacol 33:574-580, 1993
39. Bard JM, Parra HJ, Douste-Blazy P, et al. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition. Metabolism 39:269-273, 1990
40. Cheung MC, Austin MA, Moulin P, et al. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis 102:107-119, 1993
41. Klausen IC, Gerdes LU, Meinertz H, et al. Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration. Eur J Clin Invest 23:240-245, 1993
42. Branchi A, Rovellini A, Fiorenza AM, et al. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients. Int J Clin Pharmacol Ther 33:345-350, 1995
43. Cobbaert C, Jukema JW, Zwinderman AH, et al. Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderate elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group. J Am Coll Cardiol 30:1491-1499, 1997
44. Dobs AS, Prasad M, Goldberg A, et al. Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs. Cardiovasc Drugs Ther 9:677-684, 1995
45. Fieseler HG, Armostrong VW, Wieland E, et al. Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: Results of a 2-year investigation. Clin Chim Acta 204:291-300, 1991
46. Maison P, Mennen L, Sapinho D, et al. A pharmacoepidemiological assessment if the effect of statins and fibrates on fibrinogen concentration. Atherosclerosis 160:155-160, 2002
47. White CM. Pharmacological effects of HMG-CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol 39:111-118, 1999
48. Rosenson RS, Tangney CC, Schaefer EJ. Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis 155:463-466, 2001
49. Song JC, White CM. Do HMG-CoA reductase inhibitors affect fibrinogen? Ann Pharmacother 35:236-241, 2001
50. Albert MA, Danielson E, Rifai PM, et al. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 286:64-70, 2001
51. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100:230-235, 1999
52. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357-362, 2001
53. Kakafika A, Tsimihodimos V, Elisaf M. Effect of atorvastatin on serum uric acid levels. Atherosclerosis 158:25, 2001
54. Youssef F, Seifalian AM, Jagroop IA, Myint F, Baker D, Mikhailidis DP, Hamilton G. The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg 23:358-364, 2002
55. Kakafika A, Liamis G, Elisaf M, Mikhailidis D. Effect of atorvastatin on serum creatinine levels. Curr Med Res Opin 17:230-231, 2001